Day One Biopharmaceuticals Inc

DAWN remains in Stage 2 Advancing with robust parabolic trend acceleration but is highly extended above steeply rising EMAs without clear pullback, making immediate execution unfavorable. Under a speculative strategy requiring distinct asymmetry, execution is deferred until a constructive retracement into rising EMA or support zones emerges. Medium-term bias stays bullish, but timing awaits a defined pullback for a higher probability entry.

• ↑Ojemda net revenue $155.4M (+172% YoY) in 2025
• ↑Prescriptions >4,600 (+180% YoY), up 15% QoQ
• ↓Sustaining adoption may falter due to entrenched therapy use